Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome



To investigate the correlation between serum 25-hydroxyvitamin D (25-OH-VD) concentrations and metabolic parameters in obese and non-obese women with polycystic ovary syndrome (PCOS).


One hundred women with PCOS were divided into two groups, obese and non-obese, according to their body mass index (BMI). Waist-to-hip ratio (WHR), Ferriman–Gallwey score, homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol, triglycerides, calcium, 25-OH-VD, LH/FSH, total testosterone, and DHEAS were measured.


The serum 25-OH-VD mean levels were 56.31% lower in the obese PCOS patients. There was an association of increased HOMA-IR, BMI, WHR, triglycerides, total testosterone, and DHEAS with decreased 25-OH-VD concentrations in the obese PCOS patients.


Low serum 25-OH-VD concentrations result from the presence of obesity and insulin resistance. However, the dependency between PCOS and hypovitaminosis D is questionable. Hypovitaminosis D should be kept in mind while managing obese women with PCOS.

This is a preview of subscription content, access via your institution.


  1. 1.

    Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861. doi:10.1056/NEJM199509283331307

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2003) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47. doi:10.1093/humrep/deh098

    Article  Google Scholar 

  3. 3.

    Utsunomiya T, Taniguchi I, Sadanaga A et al (1993) Insulin resistance in non-obese patients with polycystic ovary syndrome. Jpn J Fertil Steri 38:77–81

    Google Scholar 

  4. 4.

    Aronne LJ, Segal KR (2002) Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res 10(Suppl 1):14S–21S. doi:10.1038/oby.2002.184

    PubMed  Article  Google Scholar 

  5. 5.

    Gambineri A, Pelusi C, Vicennati V et al (2002) Obesity and the polycystic ovary syndrome. Int J Obes 26:883–896. doi:10.1038/sj.ijo.0801994

    Article  CAS  Google Scholar 

  6. 6.

    Dale PO, Tanbo T, Vaaler S et al (1992) Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 58:487–491

    PubMed  CAS  Google Scholar 

  7. 7.

    Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R (2003) The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 20:451–454. doi:10.1046/j.1464-5491.2003.00971.x

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Bourlon PM, Billaudel B, Faure–Dussert A (1999) Influence of vitamin D3 deficiency and 1, 25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 160:87–95. doi:10.1677/joe.0.1600087

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820–825

    PubMed  CAS  Google Scholar 

  10. 10.

    Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419. doi:10.1007/BF00280883

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Wickenheisser JK, Nelson–DeGrave VL, McAllister JM (2006) Human ovarian theca cells in culture. Trends Endocrinol Metab 17:65–71. doi:10.1016/j.tem.2006.01.003

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Zborowski JV, Talbott EO, Cauley JA (2001) Polycystic ovary syndrome, androgen excess, and the impact on bone. Obstet Gynecol Clin North Am 28:135–151, vii–viii. doi:10.1016/S0889-8545(05)70190-X

  14. 14.

    Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf) 48:169–173. doi:10.1046/j.1365-2265.1998.3691182.x

    Article  CAS  Google Scholar 

  15. 15.

    Ferrannini E, Natali A, Bell P et al (1997) Insulin resistance and hypersecretion in obesity group for the study of insulin resistance (EGIR). J Clin Invest 100:1166–1173. doi:10.1172/JCI119628

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS (2000) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 15:1266–1274. doi:10.1093/humrep/15.6.1266

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Pasquali R, Casimirri F (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 39:1–16. doi:10.1111/j.1365-2265.1993.tb01744.x

    Article  CAS  Google Scholar 

  18. 18.

    Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146. doi:10.2337/diacare.22.1.141

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig R, Mann K, Janssen OE (2006) Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 114:577–583. doi:10.1055/s-2006-948308

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG (2003) Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 52:713–719. doi:10.1016/S0026-0495(03)00031-3

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Dunaif A, Segal KR, Futterweit W et al (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174. doi:10.2337/diabetes.38.9.1165

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    The Committee for Reproductive and Endocrine in Japan Society of Obstetrics and Gynecology (1993) Annual report (1991–1992) for the determination of diagnostic criteria for polycystic ovary syndrome. Acta Obstet Gynaecol Jpn 45:1359–1367 (in Japanese)

    Google Scholar 

  23. 23.

    Zemel MB (2002) Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 21:146S–151S

    PubMed  CAS  Google Scholar 

  24. 24.

    Holecki M, Zahorska-Markiewicz B, Janowska J, Mizia-Stec K, Zak-Golab A, Olszanecka-Glinianowicz M, Wojaczynska-Stanek K, Nieszporek T, Wiecek A (2007) Osteoprotegerin—does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? Endokrynol Pol 58:7–10

    PubMed  Google Scholar 

  25. 25.

    Yanoff LB, Parikh SJ, Spitalnik A et al (2006) The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese black Americans. Clin Endocrinol (Oxf) 64:523–529. doi:10.1111/j.1365-2265.2006.02502.x

    Article  CAS  Google Scholar 

  26. 26.

    Scragg R, Sowers M, Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813–2818. doi:10.2337/diacare.27.12.2813

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Zella JB, McCary LC, DeLuca HF (2003) Oral administration of 1, 25-dihydroxyvitamin D3 completely protects NOD mice from insulin dependent diabetes mellitus. Arch Biochem Biophys 417:77–80. doi:10.1016/S0003-9861(03)00338-2

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Isaia G, Giorgino R, Adami S (2001) High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24:1496. doi:10.2337/diacare.24.8.1496

    Google Scholar 

  29. 29.

    Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG (2008) Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril Oct 16 (Epub ahead of print) PMID: 18930208.

  30. 30.

    Baynes KC, Boucher BJ, Feskens EJ, Kromhout D (1997) Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 40:344–347. Published erratum appears in Diabetologia 1997 40(7):870. doi:10.1007/s001250050685

    Google Scholar 

  31. 31.

    Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP (1999) Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 64:430–435. doi:10.1016/S0039-128X(99)00012-4

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH (1988) Low circulating vitamin D in obesity. Calcif Tissue Int 43:199–201. doi:10.1007/BF02555135

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest statement


Author information



Corresponding author

Correspondence to Recep Yildizhan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yildizhan, R., Kurdoglu, M., Adali, E. et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 280, 559 (2009).

Download citation


  • Polycystic ovary syndrome
  • 25-Hydroxyvitamin D
  • Insulin resistance
  • Obese
  • Non-obese